Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Remme

Showing results (191-200 of 236) with videos related to

Pageof 24
Sort By:
European Journal of Heart Failure|August 19, 2007
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trialLars G Olsson, Karl Swedberg, John G F Cleland, et al.
Lancet (London, England)|September 14, 1985
Improved survival after early thrombolysis in acute myocardial infarction. A randomised trial by the Interuniversity Cardiology Institute in The NetherlandsM L Simoons, P W Serruys, M vd Brand, et al.
Acta Leidensia|January 1, 1990
Large scale ivermectin distribution and its epidemiological consequencesJ Remme, G De Sole, K Y Dadzie, et al.
European Journal of Heart Failure|June 22, 2007
Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMETMarco Metra, Christian Torp-Pedersen, John G F Cleland, et al.
European Journal of Heart Failure|June 1, 2005
Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial)Andrea Di Lenarda, Willem J Remme, Andrew Charlesworth, et al.
European Journal of Heart Failure|January 24, 2009
Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trialsWayne C Levy, Dariush Mozaffarian, David T Linker, et al.
Journal of the American College of Cardiology|April 25, 2006
A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)John G F Cleland, Andrew Charlesworth, Jacobus Lubsen, et al.
European Heart Journal|October 31, 1998
EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery diseaseM L Simoons, J Vos, P J de Feyter, et al.
European Journal of Heart Failure|August 25, 2007
Effect of carvedilol and metoprolol on the mode of death in patients with heart failureWillem J Remme, John G Cleland, Leif Erhardt, et al.
Journal of the American College of Cardiology|April 1, 1986
Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survivalM L Simoons, P W Serruys, M van den Brand, et al.
Pageof 24

Showing results (191-200 of 236) with videos related to

Sort By:
Pageof 24
European Journal of Heart Failure|August 19, 2007
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trialLars G Olsson, Karl Swedberg, John G F Cleland, et al.
Lancet (London, England)|September 14, 1985
Improved survival after early thrombolysis in acute myocardial infarction. A randomised trial by the Interuniversity Cardiology Institute in The NetherlandsM L Simoons, P W Serruys, M vd Brand, et al.
Acta Leidensia|January 1, 1990
Large scale ivermectin distribution and its epidemiological consequencesJ Remme, G De Sole, K Y Dadzie, et al.
European Journal of Heart Failure|June 22, 2007
Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMETMarco Metra, Christian Torp-Pedersen, John G F Cleland, et al.
European Journal of Heart Failure|June 1, 2005
Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial)Andrea Di Lenarda, Willem J Remme, Andrew Charlesworth, et al.
European Journal of Heart Failure|January 24, 2009
Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trialsWayne C Levy, Dariush Mozaffarian, David T Linker, et al.
Journal of the American College of Cardiology|April 25, 2006
A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)John G F Cleland, Andrew Charlesworth, Jacobus Lubsen, et al.
European Heart Journal|October 31, 1998
EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery diseaseM L Simoons, J Vos, P J de Feyter, et al.
European Journal of Heart Failure|August 25, 2007
Effect of carvedilol and metoprolol on the mode of death in patients with heart failureWillem J Remme, John G Cleland, Leif Erhardt, et al.
Journal of the American College of Cardiology|April 1, 1986
Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survivalM L Simoons, P W Serruys, M van den Brand, et al.
Pageof 24